Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | SHBG | P04278 | 6/20 | 0.69 |
| ▸ | SERPINA6 | P08185 | 6/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.69 |
| ▸ | TSHR | P16473 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.69 |
| ▸ | SNCA | P37840 | 4/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.69 |
| ▸ | PGR | P06401 | 3/20 | 0.69 |
| ▸ | AR | P10275 | 3/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.69 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.69 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.69 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itruvone SCHEMBL18708951 | 1.00 | LMNA (0.69) | LMNACYP3A4HSD17B10SHBGSERPINA6 | |
| Itruvone SCHEMBL15853688 | 1.00 | LMNA (0.69) | LMNACYP3A4HSD17B10SHBGSERPINA6 | |
| SCHEMBL8994128 | 0.89 | LMNA (0.70) | LMNACYP3A4HSD17B10SHBGSERPINA6 | |
| SCHEMBL13046037 | 0.88 | CYP17A1 (0.69) | LMNACYP3A4HSD17B10SHBGSERPINA6 | |
| SCHEMBL3748842 | 0.88 | CYP17A1 (0.69) | LMNACYP3A4HSD17B10SHBGSERPINA6 | |
| SCHEMBL3373116 | 0.88 | CYP17A1 (0.69) | LMNACYP3A4HSD17B10SHBGSERPINA6 | |
| SCHEMBL8369957 | 0.87 | LMNA (0.67) | LMNACYP3A4HSD17B10SHBGSERPINA6 | |
| SCHEMBL8369956 | 0.87 | LMNA (0.67) | LMNACYP3A4HSD17B10SHBGSERPINA6 | |
| SCHEMBL2834232 | 0.86 | LMNA (0.54) | LMNACYP3A4HSD17B10SHBGSERPINA6 | |
| SCHEMBL10929607 | 0.86 | LMNA (0.66) | LMNACYP3A4HSD17B10SHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217067-A1 | INTRANASAL DRUG DELIVERY SYSTEM | VISTAGEN THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250312544-A1 | INTRANASAL DRUG DELIVERY SYSTEM | VISTAGEN THERAPEUTICS, INC. | 2025-10-09 | — | — | US | claimed |
| US-20250312356-A1 | TREATMENT OF DYSMENORRHEA | VISTAGEN THERAPEUTICS, INC. | 2025-10-09 | — | — | US | claimed |
| WO-2022204827-A1 | APPLICATION OF HALCINONIDE AND DERIVATIVES THEREOF FOR PREPARING DRUG TREATING AND/OR PREVENTING CEREBROVASCULAR DISEASE | 兰州大学 | 2022-10-06 | — | — | WO | claimed |
| CN-113069460-A | Application of halcinonide and derivatives thereof in preparation of drugs for treating and/or preventing cerebrovascular diseases | 兰州大学 | 2021-07-06 | — | — | CN | claimed |
| US-10322138-B2 | Treatment of depressive disorders | PHERIN PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | claimed |
| EP-2938346-B1 | USE OF PREGN-4-EN-20-YN-3-ONE FOR THE TREATMENT OF DEPRESSIVE DISORDERS | PHERIN PHARM INC (US) | 2017-04-05 | — | — | EP | claimed |
| EP-2938346-A1 | USE OF PREGN-4-EN-20-YN-3-ONE FOR THE TREATMENT OF DEPRESSIVE DISORDERS | Pherin Pharmaceuticals, Inc. (US) | 2015-11-04 | — | — | EP | claimed |
| WO-2014105620-A1 | USE OF PREGN-4-EN-20-YN-3-ONE FOR THE TREATMENT OF DEPRESSIVE DISORDERS | PHERIN PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | WO | claimed |
| US-20140187524-A1 | Treatment of Depressive Disorders | PHERIN PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | claimed |
| WO-2025217067-A1 | INTRANASAL DRUG DELIVERY SYSTEM | VISTAGEN THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250312544-A1 | INTRANASAL DRUG DELIVERY SYSTEM | VISTAGEN THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250312356-A1 | TREATMENT OF DYSMENORRHEA | VISTAGEN THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| WO-2022204827-A1 | APPLICATION OF HALCINONIDE AND DERIVATIVES THEREOF FOR PREPARING DRUG TREATING AND/OR PREVENTING CEREBROVASCULAR DISEASE | 兰州大学 | 2022-10-06 | — | — | WO | disclosed |
| CN-113069460-B | Application of halcinonide and derivatives thereof in preparation of drugs for treating and/or preventing cerebrovascular diseases | 兰州大学 | 2022-02-08 | — | — | CN | disclosed |
| WO-1997036596-A9 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | — | 1997-12-04 | — | — | WO | disclosed |
| WO-1997036596-A1 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | PHERIN PHARMACEUTICALS, INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0775154-A1 | PREGNANES AND CHOLANES AS NEUROCHEMICAL INITIATORS OF CHANGE IN HYPOTHALAMIC FUNCTION | PHERIN CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5563131-A | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods | PHERIN CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| WO-1996004296-A1 | PREGNANES AND CHOLANES AS NEUROCHEMICAL INITIATORS OF CHANGE IN HYPOTHALAMIC FUNCTION | PHERIN CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322138-B2 | Treatment of depressive disorders | HSD3B1, HSD17B3, HSD3B2 | LMNA 2137/4885CYP3A4 291/4885HSD17B10 53/4885 |
| US-20250312356-A1 | TREATMENT OF DYSMENORRHEA | PTGER3, HSD17B11, PTGER1 | LMNA 2705/4885CYP3A4 1842/4885HSD17B10 218/4885 |
| US-20140187524-A1 | Treatment of Depressive Disorders | HSD3B1, HSD17B3, HSD3B2 | LMNA 2137/4885CYP3A4 291/4885HSD17B10 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.